Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Medicine

Moderna Submits Request for Emergency Use of COVID-19 Vaccine for Young Children

Brian Park, PharmD

May 17, 2022

The KidCOVE study included children 6 months to less than 6 years of age who received either two 25mcg doses of mRNA-1273 or placebo, separated by 28 days.

Imaging

GE Healthcare Contrast Media Products in Short Supply

Brian Park, PharmD

May 16, 2022

Visipaque and Omnipaque are radiographic contrast agents.

Metabolic

Tirzepatide Superior to Placebo in Weight Loss Study

Brian Park, PharmD

May 16, 2022

The SURMOUNT-1 trial evaluated tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity or are overweight.

General Medicine

FDA Panel Will Meet to Discuss Multiple COVID-19 Vaccine EUA Requests

Brian Park, PharmD

May 13, 2022

The panel intends to discuss the SARS-CoV-2 strain composition of COVID-19 vaccines, in addition to authorization for use in younger children.

Practice Management

Warning Letters Sent to Online Pharmacies Illegally Selling Schedule II Stimulants

Brian Park, PharmD

May 12, 2022

The FDA urges consumers to buy prescription drugs, such as Adderall, from state-licensed US pharmacies or physicians located in the US.

Arrhythmia

Camzyos Approved for Obstructive Hypertrophic Cardiomyopathy

Brian Park, PharmD

May 11, 2022

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin.

General Cardiology

FDA Authorizes Shelf-Life Extension for Certain COVID-19 Vaccines

Brian Park, PharmD

May 6, 2022

The FDA has extended shelf-life for the Janssen COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine following a thorough review of data submitted by both manufacturers.

Pediatric Cardiology

Veklury Approval Expanded to Include COVID-19 Treatment in Younger Children

Brian Park, PharmD

May 5, 2022

The approval was supported by data from a phase 2/3 CARAVAN study.

General Medicine

Ampreloxetine Misses Endpoint in Second Neurogenic Orthostatic Hypotension Trial

Brian Park, PharmD

April 28, 2022

The phase 3 REDWOOD study included patients aged 30 years and older with primary autonomic failures and symptomatic neurogenic orthostatic hypotension.

Metabolic

Leqvio Approved as Twice-Yearly Injection to Lower LDL-C in High-Risk Patients

Brian Park, PharmD

January 6, 2022

The approval was based on data from the ORION-9, ORION-10, and ORION-11 trials that evaluated Leqvio in patients 18 years of age and older with HeFH or clinical ASCVD.

Next post in Metabolic